… scientific literature and evidence of EGFR TKIs as first-line therapy from the first-generation
EGFR TKIs to conceptually proposed fourth-generation EGFR TKI, and also recommend the …

… Mutation at the TK domain of EGFR results … lung cancers harboring constitutively active
mutant EGFR are exquisitely sensitive to the apoptotic or growth inhibitory activities of EGFR TKIs …

… EGFR TKIs is around 9–12 months in EGFR-mutant NSCLC patients. The acquired resistance
to EGFR TKIs including third-generation EGFR TKI … NSCLC and oncogenic EGFR pathway …

… We identified all patients with metastatic EGFR exon19del or L858R-mutant lung cancers
treated with first/second-generation EGFR tyrosine kinase inhibitors (TKIs) with pretreatment …

… factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) – … with EGFR mutation-positive
non-small cell lung cancer (NSCLC). Given the long-term exposure of such patients to EGFR-TKIs, …

… for EGFR mutations. Our case–control study revealed that lung cancers harbouring EGFR
mutation … of tobacco smoking, whereas lung cancers without EGFR mutations are very much …

… The second-generation EGFR-TKI dacomitinib has also recently been approved for … of
EGFR-TKIs in this setting, including EGFR-TKIs as monotherapy or in combination with other TKIs / …

… Lung cancer is the leading cause of cancer-related death … drugs such as EGFR tyrosine
kinase inhibitors (TKI) and immune-… therapeutic outcome in non–small cell lung cancer (NSCLC). …

… Purpose: All patients with EGF receptor (EGFR)–mutant lung cancers eventually develop
acquired resistance to EGFR tyrosine kinase inhibitors (TKI). Smaller series have identified …

… -EGFR treatments. This review summarizes the clinical development of EGFR tyrosine kinase
inhibitors, … the still unfolding story of EGFR tyrosine kinase inhibitors (TKIs) in lung cancer. …